PMID- 26675376
OWN - NLM
STAT- MEDLINE
DCOM- 20161221
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 7
DP  - 2016 Feb 16
TI  - Analysis of risk and predictors of brain radiation necrosis after radiosurgery.
PG  - 7773-9
LID - 10.18632/oncotarget.6532 [doi]
AB  - In this study, we examined the factors contributing to brain radiation necrosis 
      and its predictors of patients treated with Cyberknife radiosurgery. A total of 
      94 patients with primary or metastatic brain tumours having been treated with 
      Cyberknife radiotherapy from Sep. 2006 to Oct. 2011 were collected and 
      retrospectively analyzed. Skull based tracking was used to deliver radiation to 
      104 target sites. and the prescribed radiation doses ranged from 1200 to 4500 cGy 
      in 1 to 8 fractions with a 60% to 87% isodose line. Radiation necrosis was 
      confirmed by imaging or pathological examination. Associations between cerebral 
      radiation necrosis and factors including diabetes, cardio-cerebrovascular 
      disease, target volume, isodose line, prescribed dosage, number of fractions, 
      combination with whole brain radiation and biologically equivalent dose (BED) 
      were determined by logistic regression. ROC curves were created to measure the 
      predictive accuracy of influence factors and identify the threshold for brain 
      radiation necrosis. Our results showed that radiation necrosis occurred in 12 
      targets (11.54%). Brain radiation necrosis was associated by BED, combination 
      with whole brain radiotherapy, and fractions (areas under the ROC curves = 
      0.892+/-0.0335, 0.650+/-0.0717, and 0.712+/-0.0637 respectively). Among these factors, 
      only BED had the capability to predict brain radiation necrosis, and the 
      threshold dose was 7410 cGy. In conclusion, BED is the most effective predictor 
      of brain radiation necrosis, with a dose of 7410 cGy being identified as the 
      threshold.
FAU - Zhuang, Hongqing
AU  - Zhuang H
AD  - Department of Radiotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of 
      Cancer Prevention and Therapy and Tianjin Lung Cancer Center, Tianjin, China.
FAU - Zheng, Yi
AU  - Zheng Y
AD  - Daqing Oilfield General Hospital, Heilongjiang, China.
FAU - Wang, Junjie
AU  - Wang J
AD  - Department of Radiotherapy, Peking University 3rd Hospital, Beijing, China.
FAU - Chang, Joe Y
AU  - Chang JY
AD  - Department of Radiation Oncology, Division of Radiation Oncology, The University 
      of Texas MD Anderson Cancer Center, Houston, TX, USA.
FAU - Wang, Xiaoguang
AU  - Wang X
AD  - Department of Radiotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of 
      Cancer Prevention and Therapy and Tianjin Lung Cancer Center, Tianjin, China.
FAU - Yuan, Zhiyong
AU  - Yuan Z
AD  - Department of Radiotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of 
      Cancer Prevention and Therapy and Tianjin Lung Cancer Center, Tianjin, China.
FAU - Wang, Ping
AU  - Wang P
AD  - Department of Radiotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of 
      Cancer Prevention and Therapy and Tianjin Lung Cancer Center, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*secondary/surgery
MH  - Child
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Necrosis
MH  - Neoplasm Staging
MH  - Neoplasms/*pathology/surgery
MH  - Prognosis
MH  - Radiation Injuries/etiology/*pathology
MH  - Radiosurgery/*adverse effects
MH  - Radiotherapy Dosage
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Young Adult
PMC - PMC4884953
OTO - NOTNLM
OT  - Cyberknife
OT  - biologically equivalent dose (BED)
OT  - brain radiation necrosis
OT  - stereotactic radiotherapy (SRT)
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2015/12/18 06:00
MHDA- 2016/12/22 06:00
PMCR- 2016/02/16
CRDT- 2015/12/18 06:00
PHST- 2015/08/19 00:00 [received]
PHST- 2015/11/25 00:00 [accepted]
PHST- 2015/12/18 06:00 [entrez]
PHST- 2015/12/18 06:00 [pubmed]
PHST- 2016/12/22 06:00 [medline]
PHST- 2016/02/16 00:00 [pmc-release]
AID - 6532 [pii]
AID - 10.18632/oncotarget.6532 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Feb 16;7(7):7773-9. doi: 10.18632/oncotarget.6532.